2023-08-15T20:00:26+00:00 2022-09-30 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE IRVINE CA 92612 990 2021-10-01 953432210 BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE BECK 6262564673 1450 EAST DUARTE ROAD DUARTE CA 91010 ROBERT W STONE PRESIDENT & CEO 2023-08-15 true Jo Ann Escasa-Haigh 999009999 Kara Adams P00023315 9497942300 2023-08-08 2021 2023-04-26 12:10:37Z Robert W Stone 1500 DUARTE ROAD DUARTE CA 91010 1311262814 false X https://www.cityofhope.org X 1979 CA TO DISCOVER AND TRANSLATE INNOVATIVE LABORATORY FINDINGS INTO NEW CLINICAL TREATMENTS BY USING PRACTICAL APPLICATIONS OF CHEMISTRY, PHYSICS AND BIOLOGY. 9 8 1244 12 2556297 1777069 185089497 154152878 17733869 25203801 108622736 93521495 27731834 15397839 339177936 288276013 0 0 0 0 180442230 195853894 0 0 146521 161404015 171745719 341846245 367599613 -2668309 -79323600 1995828082 1755270549 537676587 626893914 1458151495 1128376635 THE SPECIFIC AND PRIMARY PURPOSE of the Beckman Research Institute of the City of Hope IS TO DIRECTLY ENGAGE IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH. Please see Schedule O for a continuation of our mission. false false 288953230 0 25203801 BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE. THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN, AND HUMIRA FOR ARTHRITIS. RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN DIABETES PROGRESSION AND TREATMENT, IMMUNOLOGY AND IMAGING, INTERFERING RNAS AND HIV TREATMENT, TOTAL SYNTHESIS OF COMPLEX AND THERAPEUTIC NATURAL PRODUCTS, MECHANISMS OF DRUG ACTION, NEUROGENESIS, STEM CELL THERAPY, DNA REPAIR AND RADIATION, AND THE IMMUNOBIOLOGY OF VIRAL INFECTION. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE -- ANALYZING A PATIENT'S UNIQUE GENETIC PROFILE TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES FOR MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT. 288953230 true true false false false false false false true true true false true true true false true false true true false false false false false false false false true true false false false false false false false false true false false false false false false true true true false false true X 505 0 true 1244 true true true false false false false false false false false false true false X 9 8 false false false false true true true true false false false false true true true true true true true false CA X Jo Ann Escasa-Haigh 6262564673 1500 EAST DUARTE ROAD DUARTE CA 91010 STEVEN B FINK Director & CHAIR of the Board 2.0 4.0 X X 0 0 0 ART NEMIROFF Director - Thru 12/31/21 2.0 0 X 0 0 0 BENHAM BADIE MD Director - Thru 6/30/22 2.0 0 X 0 0 0 CHARLOTTE HUBBERT PHD Director 2.0 0 X 0 0 0 Debbie C Thurmond PHD Director - Beg. 7/1/22; Professor 60.0 0 X 436128 0 75859 EMMET STEPHENSON Director 2.0 0 X 0 0 0 ERNIE SO Director - Thru 12/31/21 2.0 2.0 X 0 0 0 GARY E FREEDMAN Director - Thru 12/31/21 2.0 0 X 0 0 0 JODY HOROWITZ MARSH Director - Thru 12/31/21 2.0 2.0 X 0 0 0 JOHN J ROSSI PHD Director - Thru 12/31/21, PROFESSOR 60.0 0 X 341785 0 72193 JULIAN HUSBANDS MD Director 2.0 0 X 0 0 0 LINDA Helen MALKAS PHD Director - thru 06/30/22, PROFESSOR 60.0 0 X 407768 0 59254 NORMAN PAYSON MD Director 2.0 0 X 0 0 0 Saro Armenian DO MPH Director - Beg. 7/1/22; Professor 2.0 0 X 0 0 0 SELWYN ISAKOW Director 2.0 2.0 X 0 0 0 TODD BINDER Director 2.0 0 X 0 0 0 CRISTIN O'CALLAHAN Gen. Counsel & Corp. Secretary - Beg. 1/1/22 15.0 46.0 X 143639 430917 121560 DONALD J MATTHEWSON Asst. Treasurer & VP, Treasury & Fin. Strategy 15.0 45.0 X 122018 366054 47752 GREGORY D SCHETINA GEN. COUNSEL & Corp. SECRETARY - Thru 12/31/21 15.0 46.0 X 316714 950142 184060 JENNIFER A PARKHURST Treasurer & CFO 15.0 46.0 X 476838 1430514 274536 ROBERT W STONE PRESIDENT & CEO 15.0 46.0 X 867012 2601035 645461 Ashley Baker Lee SVP, Research Operations 30.0 30.0 X 495549 468549 105701 David Horne PhD Vice Provost & Deputy Director 51.0 9.0 X 752847 132855 107300 Debra Fields EVP & Chief Transformation Officer 15.0 45.0 X 329274 987822 272088 Mark Hulse Chief Digital Officer 15.0 45.0 X 374801 1124402 211800 Steven T Rosen MD Provost & Chief Scientific Officer 33.0 27.0 X 1039403 837223 267963 HARLAN LEVINE MD President, Health Innovation & policy 18.0 42.0 X 638755 1490428 306391 KRISTIN BERTELL CHIEF PHILANTHROPY OFFICER 3.0 57.0 X 64558 1226609 221087 MICHAEL A CALIGIURI MD President, COHNMC 5.0 55.0 X 228821 2320624 330836 Patrick Anderson Chief Information Officer - Thru 12/31/21 15.0 45.0 X 256320 768959 53256 VIJAY TRISAL MD Chief Medical Officer 6.0 54.0 X 128837 1159538 110535 Cornelis Van den Berg Former Officer 15.0 45.0 X 192240 576720 78516 Jeffrey Walker Former Officer 15.0 30.0 X 84698 254094 15644 7698005 17126485 3561792 294 true true false Mintz Levin Cohn Ferris Glovsky and Popeo PC 2049 Century Park East Ste 300 Los Angeles CA 90067 Legal Services 3128976 Jones Day 555 South Flower Street 50th Floor Los Angeles CA 90071 Legal Services 2125193 Durie Tangri LLP 953 E 3rd Street Ste 100 Los Angeles CA 90013 Legal Services 1897962 Fish & Richardson PC 633 West 5th Street 26th Floor Los Angeles CA 90071 Legal Services 1343078 LCS Constructors Inc 15205 Alton Parkway Irvine CA 92618 Construction Services 1333556 26 48853255 98626185 6673438 154152878 Research Activities 541700 24213257 24213257 Specialized Lab Revenue 541380 659554 659554 Graduate Education Program 611310 292150 292150 Rental Income - Graduate Education 721310 38840 38840 0 0 0 0 25203801 14429552 14429552 12755042 12755042 86500 0 86500 0 86500 86500 1102078744 1022986801 79091943 0 79091943 79091943 INVESTMENT INCOME FROM K-1'S 901101 2556297 2556297 0 0 0 0 2556297 288276013 25203801 2556297 106363037 X 7033214 2227615 4747948 57651 352259 0 352259 0 152712668 131522346 21132231 58091 9190968 8150312 1040619 37 16510042 13968950 2530283 10809 10054743 8435050 1612843 6850 6570522 31347 6539175 44681 44681 2657517 2657517 47754950 31677527 16073876 3547 2790755 1982338 808196 221 5835364 5499709 335533 122 9829543 6505712 3323102 729 6409110 6409110 13172671 9356855 3814775 1041 1356022 963214 392701 107 564976 402074 162858 44 4702704 4266071 436633 27539979 20384331 7149991 5657 1158745 823083 335570 92 Lab/Medical Supplies & Equipment 29264258 27736118 1527568 572 Repairs & Maintenance 5715724 4062844 1652429 451 UBIT & Excise Taxes 1379126 979625 399392 109 Dues & Subscriptions 1022882 726577 296224 81 3976190 2842422 1133458 310 367599613 288953230 78499862 146521 3681035 7545012 71476960 17336792 55481838 35176879 0 13521672 0 0 0 0 5377157 5753644 301461 306843 583082378 282902376 310505148 300180002 547030523 282925843 912730798 897988765 0 89243162 194535097 1995828082 1755270549 54947308 42372436 10894125 9407922 50723925 50104751 0 50000000 50000000 371111229 475008805 537676587 626893914 X 1427028168 1100918157 31123327 27458478 1458151495 1128376635 1995828082 1755270549 X -79323600 -259897637 9446377 X false true X true true true X City of Hope National Medical Center Duarte CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1038955240 29999 -121654359 180230 917150650 813672523 30000 225523936 271219 1038955240 765484958 30000 48653478 495913 813672523 750855062 14850 15019931 404885 765484958 693069392 30113 58203028 447471 750855062 0.97 0.0155 0.0145 false false 6332218 6332218 374906720 153245388 221661332 190426533 129656988 60769545 11416907 0 11416907 300180002 1648768 F Alternative Investments 895154934 F Equity Interests 1185063 F 897988765 Due from Affiliates 144354703 Workers Compensation Receivable 349015 Security Deposits 2873 Right-of-use operating lease assets 49828506 194535097 Due to Affiliates 420770279 Right-of-Use Operating Lease Liability 49911407 Interest Rate Swap Liability 1110003 Workers Compensation Liability 1926635 Bond Issuance Premium 1290481 475008805 X Schedule D, Part V, Line 4 Intended uses of endowment funds BECKMAN RESEARCH INSTITUTE HAS BOARD DESIGNATED ASSETS OR QUASI-ENDOWMENT FUNDS AND OTHER PERMANENT ENDOWMENT FUNDS WHICH ARE AVAILABLE TO FUND FUTURE RESEARCH PROGRAMS, CAPITAL EXPENDITURES AND OTHER EXPANSION NEEDS AS DETERMINED BY MANAGEMENT AND THE BOARD OF DIRECTORS. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE FOLLOWING PARAGRAPH IS FROM THE CITY OF HOPE CONSOLIDATED AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 (WHICH INCLUDES CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, THE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, ACCESSHOPE, LLC, the CITY OF HOPE AUXILIARIES (AUXILIARIES) and COH HoldCo, Inc.: ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE, AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AS OF SEPTEMBER 30, 2022 OR 2021. Central America and the Caribbean 0 0 Investments 181401263 Central America and the Caribbean 0 1 Conference Travel Attending Research Symposiums 556 Europe (Including Iceland and Greenland) 0 1 Program Services Research Activities 177879 Europe (Including Iceland and Greenland) 0 25 Conference Travel Attending Research Symposiums 186683 North America (Canada & Mexico only) 0 0 Investments 25263915 North America (Canada & Mexico only) 0 7 Conference Travel Attending Research Symposiums 19346 South Asia 0 1 Conference Travel Attending Research Symposiums 2507 0 35 0 0 0 35 207052149 0 207052149 true false true true true false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH ASIA-Accrual X true true X X X X X X false true false false false false false true false LINDA Helen MALKAS PHD Director - thru 06/30/22, PROFESSOR 403196 0 0 0 4572 0 43500 0 15754 0 467022 0 0 0 JOHN J ROSSI PHD Director - Thru 12/31/21, PROFESSOR 334761 0 4062 0 2962 0 43500 0 28693 0 413978 0 0 0 Debbie C Thurmond PHD Director - Beg. 7/1/22; Professor 415819 0 13799 0 6510 0 43500 0 32359 0 511987 0 0 0 Cornelis Van den Berg Former Officer 115389 346167 47865 143595 28986 86958 13163 39489 6466 19398 211869 635607 8039 24117 Jeffrey Walker Former Officer 53117 159351 0 0 31581 94743 1479 4436 2432 7297 88609 265827 0 0 DONALD J MATTHEWSON Asst. Treasurer & VP, Treasury & Fin. Strategy 87560 262680 20711 62133 13747 41241 8976 26928 2962 8886 133956 401868 0 0 CRISTIN O'CALLAHAN Gen. Counsel & Corp. Secretary - Beg. 1/1/22 87966 263898 31179 93537 24494 73482 18241 54723 12149 36447 174029 522087 0 0 JENNIFER A PARKHURST Treasurer & CFO 205167 615501 168406 505218 103265 309795 57200 171600 11434 34302 545472 1636416 92758 278274 GREGORY D SCHETINA GEN. COUNSEL & Corp. SECRETARY - Thru 12/31/21 155010 465030 118689 356067 43015 129045 34199 102597 11816 35448 362729 1088187 30304 90912 ROBERT W STONE PRESIDENT & CEO 401281 1203842 361482 1084445 104249 312748 151428 454284 9937 29812 1028377 3085131 107159 321478 Ashley Baker Lee SVP, Research Operations 289868 262868 126012 126012 79669 79669 36821 36821 16029 16030 548399 521400 18412 18412 Debra Fields EVP & Chief Transformation Officer 159733 479199 135278 405834 34263 102789 54590 163770 13432 40296 397296 1191888 34239 102717 David Horne PhD Vice Provost & Deputy Director 436430 77017 201191 35504 115226 20334 56793 10023 34411 6073 844051 148951 30397 5365 Mark Hulse Chief Digital Officer 174245 522734 122455 367365 78101 234303 45888 137664 7062 21186 427751 1283252 79522 238566 Steven T Rosen MD Provost & Chief Scientific Officer 492866 396996 399741 321985 146796 118242 134881 108644 13535 10903 1187819 956770 104524 84192 Patrick Anderson Chief Information Officer - Thru 12/31/21 133356 400067 60203 180609 62761 188283 10259 30777 3055 9165 269634 808901 42962 128886 KRISTIN BERTELL CHIEF PHILANTHROPY OFFICER 29879 567706 26868 510496 7811 148407 8729 165843 2326 44189 75613 1436641 0 0 MICHAEL A CALIGIURI MD President, COHNMC 98620 1000164 79427 805523 50774 514937 25190 255467 4504 45675 258515 2621766 47674 483491 HARLAN LEVINE MD President, Health Innovation & policy 296423 691654 264632 617474 77700 181300 79228 184866 12689 29608 730672 1704902 60959 142238 VIJAY TRISAL MD Chief Medical Officer 64417 579757 28674 258065 35746 321716 6521 58691 4532 40791 139890 1259020 0 0 Schedule J, Part I, Line 1a First-class or charter travel THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE PERMITS FIRST CLASS TRAVEL FOR CERTAIN OFFICERS, DIRECTORS, AND KEY EXECUTIVES IN LIMITED CIRCUMSTANCES WHEN SPECIFIED TRAVEL CRITERIA ARE MET. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE BECKMAN RESEARCH INSTITUTE HAS A NON QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (B) (III). PRIOR TO VESTING, THE ANNUAL CONTRIBUTION AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (C). PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. For CALENDAR YEAR 2021, THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: Robert W. Stone - $43,349 Michael A. Caligiuri - $201,487 Steven T. Rosen - $35,425 Mark Hulse - $69,283 Debra Fields - $22,506 Kristin Bertell - $12,302 Gregory D. Schetina - $12,186 Vijay Trisal - $125,176 Patrick Anderson - $47,025 Ashley Lee - $15,833 David Horne - $14,060 Cornelis Van Den Berg - $15,942 Schedule J, Part I, Line 7 Non-fixed payments THE BECKMAN RESEARCH INSTITUTE 'S EXECUTIVES AND CERTAIN KEY EMPLOYEES ARE ELIGIBLE TO RECEIVE INCENTIVE COMPENSATION UNDER AN ANNUAL INCENTIVE PLAN (AIP) TIED TO THREE (3) KEY PERFORMANCE INDICATORS AND TWO OR MORE INDIVIDUAL OBJECTIVES. THE KEY PERFORMANCE INDICATORS REFLECT KEY AREAS OF STRATEGIC FOCUS AND THE EXEMPT HEALTHCARE MISSION OF THE CITY OF HOPE AND AFFILIATES AND ARE BOTH FINANCIAL AND NON-FINANCIAL. THE POTENTIAL INCENTIVE COMPENSATION IS BASED ON A WEIGHTED AVERAGE AMONG ALL INDICATORS AND IS PAID AS A PERCENTAGE OF EACH INDIVIDUAL PARTICIPANT'S BASE COMPENSATION. THE KEY PERFORMANCE INDICATORS ARE WEIGHTED AT 50 PERCENT AND THE INDIVIDUAL OBJECTIVES ARE WEIGHTED AT 50 PERCENT. THE AIP IS UNDER THE CONTROL OF, AND ADMINISTERED BY, THE INDEPENDENT DIRECTORS SERVING ON THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE. TO BE ELIGIBLE, THE PARTICIPANTS IN THE AIP MUST BE EMPLOYED BY THE MEDICAL FOUNDATION AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. CITY OF HOPE MAY, IN ITS DISCRETION, CANCEL ALL OR A PORTION OF ANY INCENTIVE PLAN PAYMENT OR AWARD TO ANY PARTICIPANT, WHETHER BEFORE OR FOLLOWING PAYMENT OF SUCH AWARD, SUBJECT TO COMPLIANCE WITH APPLICABLE LAW, UNDER THE FOLLOWING CIRCUMSTANCES (CANCELLATION POLICY): A) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY RESTATES OR OTHERWISE ADJUSTS THE ANNUAL PERFORMANCE MEASUREMENT CALCULATION IN A MANNER THAT WOULD REDUCE THE SIZE OF THE AWARD OR PAYMENT, OR; B) AN INCENTIVE PLAN PAYMENT OR AWARD IS MADE FOR A FISCAL PERIOD AND CITY OF HOPE SUBSEQUENTLY DETERMINES THAT ONE OF MORE OF THE ANNUAL PERFORMANCE MEASUREMENT CALCULATIONS ON WHICH THE AWARD IS BASED OR IS PAID ARE MATERIALLY INACCURATE. THE AIP INCENTIVE COMPENSATION EARNED FOR FISCAL YEAR 2021 WAS PAID IN CALENDAR YEAR 2021 AND THESE AMOUNTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (B)(II). ADDITIONALLY, THE BECKMAN RESEARCH INSTITUTE HAS AN EXECUTIVE LONG-TERM INCENTIVE (LTI) PLAN FOR CERTAIN EXECUTIVES WHICH IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM FOR ACHIEVING KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE PLAN ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE PERFORMANCE PERIOD OF THE PLAN (CYCLE 7) RAN FROM OCTOBER 1, 2018 THROUGH SEPTEMBER 30, 2021 WITH A NEW THREE-YEAR PERFORMANCE PERIOD BEGINNING EACH OCTOBER 1ST THEREAFTER (E.G., CYCLE 8 RUNS FROM OCTOBER 1, 2019 THROUGH SEPTEMBER 30, 2022). TO BE ELIGIBLE TO PARTICIPATE IN ANY PAYOUT UNDER THE PLAN, PARTICIPANTS MUST BE ACTIVELY EMPLOYED BY THE BECKMAN RESEARCH INSTITUTE AT THE TIME OF THE INCENTIVE PLAN PAYMENT, AND BE MEETING OR EXCEEDING PERFORMANCE EXPECTATIONS. WHILE THE PLAN DOES MEET THE REQUIREMENTS FOR A SUBSTANTIAL RISK OF FORFEITURE, AS OF THE CALENDAR YEAR ENDING DECEMBER 31, 2021, THE POTENTIAL LTI AMOUNTS HAVE BEEN ESTIMATED AND ACCRUED DURING THE CURRENT TAX YEAR AND ARE REPORTED AS DEFERRED COMPENSATION TO THE PLAN PARTICIPANTS IN SCHEDULE J, PART II, COLUMN (C). THE LTI PLAN IS SUBJECT TO THE SAME CANCELLATION POLICY AS THE AIP DESCRIBED PREVIOUSLY. PARTICIPANTS WHO MET THE ELIGIBILITY CRITERIA RECEIVED A PAYOUT OF PLAN CYCLE 7 LTI INCENTIVES (OCTOBER 1, 2018 THROUGH SEPTEMBER 30, 2021) IN DECEMBER 2021. THESE AMOUNTS HAVE BEEN REFLECTED IN SCHEDULE J, PART II, COLUMN (B)(II). Schedule J, Part II Employees serving as members of the board of directors JOHN J. ROSSI, PH.D., LINDA MALKAS, PH.D., and Debbie Thurmond, Ph.D. were MEMBERS OF THE BOARD OF DIRECTORS OF THE BECKMAN RESEARCH INSTITUTE AND were ALSO EMPLOYEES of THE BECKMAN RESEARCH INSTITUTE. DR. ROSSI IS A PROFESSOR AND DIRECTOR OF MOLECULAR MEDICINE AND WAS THE DEAN OF THE CITY OF HOPE'S IRELL AND MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. DR. MALKAS IS A PROFESSOR AND DEPUTY DIRECTOR FOR BASIC RESEARCH FOR THE CANCER CENTER. Dr. Thurmond is director of the Arthur Riggs Diabetes & Metabolism Research Institute and a research scientist, professor and the founding chair of the newly created Department of Molecular and Cellular Endocrinology. Saro Armenian, D.O., M.P.H was a member of the board of directors of the Beckman RESEARCH INSTITUTE AND was employed by the City of Hope Medical Group. Dr. Armenian is the Barron Hilton Chair and Professor of Pediatrics and the Director of the Division of Outcomes Research, within the Department of Population Sciences at City of Hope. None of these individuals were COMPENSATED FOR THEIR SERVICES AS Members OF THE BECKMAN RESEARCH INSTITUTE'S BOARD OF DIRECTORS. COMPENSATION earned by those individuals employed by The Beckman Research Institute IS reported on Form 990, Part VII, Section A and subsequently ON SCHEDULE J, PART II. A California Health Facilities Financing Authority 521643828 13033LN37 2012-11-14 57928340 Refund prior issue/capital projects false false false B California Health Facilities Financing Authority 521643828 000000000 2017-02-10 32680000 Refunding Issue false false false A 37002495 0 57928742 0 0 0 534551 0 0 9853233 47540958 0 2014 true false true true B 0 0 32680000 0 0 0 180000 0 0 0 32500000 0 2017 true false true true A false true true true true true 0.0081 0.0 0.0081 false false true B false true true true true true 0.0115 0.0 0.0115 false false true A false false false true true true Wells Fargo Bank NA 30.0 false false false false true B false false false true true true Wells Fargo Bank NA 25.8 false false false false true A true B true Schedule K, Part I, Column (e) Line A AN ELECTION WAS MADE UNDER 1.150-1(C)(3) TO TREAT THE BOND ISSUE AS TWO SEPARATE ISSUES AND WAS REPORTED ON TWO SEPARATE FORMS 8038. ONE WAS FOR REFUNDING THE CITY OF HOPE NATIONAL MEDICAL CENTER'S CITY OF DUARTE CERTIFICATES OF PARTICIPATION SERIES 1999A. THE OTHER WAS FOR REFUNDING (1) THE CITY OF HOPE NATIONAL MEDICAL CENTER PROJECT SERIES 2006A, B, C ISSUES AND (2) THE BECKMAN RESEARCH INSTITUTE'S 2007 CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY ISSUE. THIS SECOND FORM 8038 REPORTED AN ISSUE PRICE OF $198,734,018. FOR PURPOSES OF SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE AMOUNT OF THE ISSUE PRICE OF $57,928,340. THE CITY OF HOPE NATIONAL MEDICAL CENTER IS REPORTING AN ISSUE PRICE OF $140,805,678. ADDITIONALLY, THE DIFFERENCE BETWEEN THE ALLOCABLE ISSUE PRICE OF $57,928,340 AND THE TOTAL PROCEEDS OF THE ISSUE OF $57,928,742 IS DUE TO INVESTMENT EARNINGS INCLUDED IN Line 3, Total proceeds of issue. Schedule K, Part I, Column (f) Line A THE 2012 ISSUE REFUNDED BECKMAN RESEARCH INSTITUTE'S TAX-EXEMPT PRIVATE PLACEMENT ISSUED ON JULY 12, 2007 THROUGH the CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY. Schedule K, Part I, Column (e) Line B THE bond issue dated FEBRUARY 10, 2017 WAS ORIGINALLY REPORTED ON A SINGLE FORM 8038 WITH AN ISSUE PRICE OF $65,360,000. FOR PURPOSES OF SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE of the City of Hope IS REPORTING its ALLOCABLE AMOUNT OF THE ISSUE PRICE OF $32,680,000. THE CITY OF HOPE NATIONAL MEDICAL CENTER IS REPORTING THE REMAINDER ON the Schedule K filed with its FORM 990. Schedule K, Part I, Column (f) Line B THE 2017 ISSUE REFUNDED $32,500,000 OF THE SERIES 2012C ISSUE WITH an ORIGINAL ISSUE DATE OF NOVEMBER 14, 2012. Schedule K, Part IV, Line 2c COLUMN A Issuer name: California Health Facilities Financing Authority The calculation for computing no rebate due was performed on 09/03/2015 Schedule K, Part IV, Line 2c COLUMN B Issuer name: California Health Facilities Financing Authority The calculation for computing no rebate due was performed on 03/04/2022 Robert Hickey Spouse of Board Member 254576 Employee Compensation false Form 990, Part III, Line 1 Organization's Mission BECKMAN RESEARCH INSTITUTE'S MISSION IS TO SUPPORT INNOVATIVE AND CREATIVE RESEARCH AND TO EDUCATE FUTURE SCIENTISTS IN THE BIOLOGICAL SCIENCES. RESEARCH IS OF THE HIGHEST CALIBER AND DIRECTED TO AN UNDERSTANDING OF THE MOLECULES AND PROCESSES OF LIFE, INCLUDING THOSE PROCESSES IMPORTANT TO THE CAUSES, PREVENTION AND CURE OF HUMAN DISEASE. BECKMAN RESEARCH INSTITUTE IS PART OF AN INTEGRATED SYSTEM THAT COMBINES BENCH AND CLINICAL RESEARCH ACTIVITIES DIRECTLY WITH PATIENT CARE, IN BOTH AN IN-PATIENT AND OUT-PATIENT SETTING. THIS INTEGRATED SYSTEM, KNOWN AS CITY OF HOPE, COLLECTIVELY REFERS TO CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, ACCESSHOPE, LLC, CITY OF HOPE AUXILIARIES and COH HoldCo Inc. AS AN INNOVATIVE BIOMEDICAL RESEARCH, TREATMENT AND EDUCATIONAL INSTITUTION, WE ARE COMMITTED TO TRANSFORMING THE FUTURE OF HEALTH. EVERY DAY WE TURN SCIENCE INTO PRACTICAL BENEFIT. WE TURN HOPE INTO REALITY. WE ACCOMPLISH THIS THROUGH EXQUISITE CARE, INNOVATIVE RESEARCH AND VITAL EDUCATION FOCUSED ON ELIMINATING CANCER, DIABETES AND OTHER LIFE-THREATENING DISEASES. CITY OF HOPE IS GUIDED BY A COMPASSIONATE, PATIENT-CENTERED PHILOSOPHY AND SUPPORTED BY A NATIONAL FOUNDATION OF PHILANTHROPY. Form 990, Part IV, Line 13 RESPONSES TO SCHEDULE E, PART I AND II: THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE IS ENGAGED IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL AND SCIENTIFIC RESEARCH AND OPERATED THE IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES (THE "GRADUATE SCHOOL") WHICH COMPLIES WITH REV. PROC. 75-50 EVEN THOUGH THE OPERATIONS OF THE GRADUATE SCHOOL REPRESENT LESS THAN 2 PERCENT OF THE ORGANIZATION'S TOTAL EXPENSES. DUE TO THE MECHANICS OF THE FORM 990 WE ARE UNABLE TO PROVIDE OUR RESPONSES DIRECTLY ON SCHEDULE E, SCHOOLS. BELOW ARE OUR RESPONSES TO SCHEDULE E, PART I AND PART II. 1. DOES THE ORGANIZATION HAVE A RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS BY STATEMENT IN ITS CHARTER, BYLAWS, OTHER GOVERNING INSTRUMENT, OR IN A RESOLUTION OF ITS GOVERNING BODY? - "YES" 2. DOES THE ORGANIZATION INCLUDE A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS IN ALL ITS BROCHURES, CATALOGUES, AND OTHER WRITTEN COMMUNICATIONS WITH THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? - "YES" 3. HAS THE ORGANIZATION PUBLICIZED ITS RACIALLY NONDISCRIMINATORY POLICY ON ITS PRIMARY PUBLICLY ACCESSIBLE INTERNET HOMEPAGE AT ALL TIMES DURING ITS TAX YEAR IN A MANNER REASONABLY EXPECTED TO BE NOTICED BY VISITORS TO THE HOMEPAGE, OR THROUGH NEWSPAPER OR BROADCAST MEDIA DURING THE PERIOD OF SOLICITATION FOR STUDENTS, OR DURING THE REGISTRATION PERIOD IF IT HAS NO SOLICITATION PROGRAM, IN A WAY THAT MAKES THE POLICY KNOWN TO ALL PARTS OF THE GENERAL COMMUNITY IT SERVES? IF "YES," PLEASE DESCRIBE. IF "NO," PLEASE EXPLAIN. - "NO" SUPPLEMENTAL RESPONSE: THE GRADUATE SCHOOL CUSTOMARILY DRAWS A SUBSTANTIAL PERCENTAGE OF ITS STUDENTS FROM LARGE GEOGRAPHIC SECTIONS OF THE UNITED STATES AND INTERNATIONALLY AND FOLLOWS A RACIALLY NONDISCRIMINATORY POLICY AS DEMONSTRATED BY ITS CURRENT ENROLLMENT OF STUDENTS OF RACIAL MINORITY GROUPS IN MEANINGFUL NUMBERS. ACCORDINGLY, THE GRADUATE SCHOOL SATISFIES THE PUBLICITY REQUIREMENTS OF SECTION 4.03 BY COMPLYING WITH SECTION 4.02 IN THAT IT INCLUDES A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY AS TO STUDENTS IN ITS CATALOGUES AND ON THE ORGANIZATION'S WEBSITE. 4. DOES THE ORGANIZATION MAINTAIN THE FOLLOWING: 4A. RECORDS INDICATING THE RACIAL COMPOSITION OF THE STUDENT BODY, FACULTY, AND ADMINISTRATIVE STAFF? - "YES" 4B. RECORDS DOCUMENTING THAT SCHOLARSHIPS AND OTHER FINANCIAL ASSISTANCE ARE AWARDED ON A RACIALLY NONDISCRIMINATORY BASIS? - "YES" 4C. COPIES OF CATALOGUES, BROCHURES, ANNOUNCEMENTS, AND OTHER WRITTEN COMMUNICATIONS TO THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? - "YES" 4D. COPIES OF ALL MATERIAL USED BY THE ORGANIZATION OR ON ITS BEHALF TO SOLICIT CONTRIBUTIONS? - "YES" 5. DOES THE ORGANIZATION DISCRIMINATE BY RACE IN ANY WAY WITH RESPECT TO: 5A. STUDENT'S RIGHTS OR PRIVILEGES? - "NO" 5B. ADMISSIONS POLICIES? - "NO" 5C. EMPLOYMENT OF FACULTY OR ADMINISTRATIVE STAFF? - "NO" 5D. SCHOLARSHIPS OR OTHER FINANCIAL ASSISTANCE? - "NO" 5E. EDUCATIONAL POLICIES? - "NO" 5F. USE OF FACILITIES? - "NO" 5.G ATHLETIC PROGRAMS? - "NO" 5H. OTHER EXTRACURRICULAR ACTIVITIES? - "NO" 6A. DOES THE ORGANIZATION RECEIVE ANY FINANCIAL AID OR ASSISTANCE FROM A GOVERNMENTAL AGENCY? - "NO" 6B. HAS THE ORGANIZATION'S RIGHT TO SUCH AID EVER BEEN REVOKED OR SUSPENDED? - "N/A" 7. DOES THE ORGANIZATION CERTIFY THAT IT HAS COMPLIED WITH THE APPLICABLE REQUIREMENTS OF SECTIONS 4.01 THROUGH 4.05 OF REV. PROC. 75-50, 1975-2 C.B. 587, COVERING RACIAL NONDISCRIMINATION? - "YES" Form 990, Part V, Line 2a COMMON PAYMASTER ARRANGEMENT MOST OF CITY OF HOPE'S OFFICERS AND KEY EMPLOYEES, AS WELL AS A FEW OF ITS HIGHEST COMPENSATED EMPLOYEES, PROVIDE SERVICES TO MORE THAN ONE CITY OF HOPE ENTITY, AND MANY OF THEM PROVIDE SERVICES TO ALL OF THE ENTITIES. FOR A NUMBER OF THESE CONCURRENTLY EMPLOYED INDIVIDUALS, THE ENTITIES HAVE DESIGNATED THE MEDICAL CENTER AS A "COMMON PAYMASTER" DEFINED IN SECTION 3121(S) OF THE INTERNAL REVENUE CODE. CITY OF HOPE REPORTS THESE CONCURRENT EMPLOYEES' TIME, EFFORT AND COMPENSATION ON THE INFORMATION RETURNS OF THE CITY OF HOPE ENTITIES BASED ON THE INDIVIDUAL'S ESTIMATE OF THEIR TIME SPENT IN AND FOR EACH ENTITY. AS "COMMON PAYMASTER", THE MEDICAL CENTER ISSUES EACH OF THESE EMPLOYEES A SINGLE COMBINED PAYCHECK AND ONE FORM W-2. Form 990, Part VI, Line 6 Classes of members or stockholders CITY OF HOPE (FEIN: 95-3435919) IS THE SOLE CORPORATE MEMBER OF THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body CITY OF HOPE, AS THE SOLE CORPORATE MEMBER OF THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE ELECTS THE DIRECTORS OF THE BECKMAN RESEARCH INSTITUTE'S BOARD OF DIRECTORS. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF THE BECKMAN RESEARCH INSTITUTE, INCLUDING: BORROWING MONEY IN THE NAME OF THE BECKMAN RESEARCH INSTITUTE OR UTILIZING PROPERTY OWNED BY THE BECKMAN RESEARCH INSTITUTE AS SECURITY FOR SUCH LOANS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE ANY OF THE CLAIMS OR DEBTS TO THE BECKMAN RESEARCH INSTITUTE EXCEPT ON PAYMENT IN FULL, OR ARBITRATE OR CONSENT TO THE ARBITRATION OF ANY DISPUTE OR CONTROVERSY OF THE BECKMAN RESEARCH INSTITUTE; MAKE, EXECUTE OR DELIVER ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR ANY BOND, CONFESSION OF JUDGMENT, CHATTEL MORTGAGE, SECURITY AGREEMENT, DEED, GUARANTY, INDEMNITY BOND, SURETY BOND, OR CONTRACT TO SELL OR BILL OF SALE OF THE PROPERTY OF THE BECKMAN RESEARCH INSTITUTE; ACQUIRE, PURCHASE, DEVELOP, IMPROVE, SELL, LEASE, OR MORTGAGE ANY CORPORATE REAL ESTATE OR ANY INTEREST THEREIN OR ENTER INTO ANY CONTRACT FOR ANY SUCH PURPOSES; OR MAKE ANY LOAN, INVESTMENT, TRANSFER OR DISPOSITION OF ANY ASSETS OF THE BECKMAN RESEARCH INSTITUTE OR ENTER INTO ANY CONTRACT OR INCUR ANY LIABILITIES ON BEHALF OF THE BECKMAN RESEARCH INSTITUTE OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS RELATING TO ITS NORMAL DAILY OPERATIONS; OR ESTABLISH CAPITAL AND OPERATING BUDGETS OR ADOPT MATERIAL CHANGES THERETO; OR ANY ACTION THAT COULD REASONABLY BE EXPECTED TO HAVE A MATERIAL ADVERSE EFFECT ON THE 501(C)(3) STATUS OF TAX EXEMPT BONDS OF CITY OF HOPE. THE FOLLOWING REQUIRE GOVERNING BODY APPROVAL (AS WELL AS THE APPROVAL OF THE SOLE CORPORATE MEMBER): THE ADOPTION OF, OR MATERIAL CHANGE IN, THE MISSION OF THE BECKMAN RESEARCH INSTITUTE; SALE OR DISPOSITION OF ALL OR SUBSTANTIALLY ALL ASSETS; MERGER AND ITS PRINCIPAL TERMS (AND ANY AMENDMENT TO THOSE TERMS); DISSOLUTION OF THE CORPORATION; ADOPTION OF OPERATING AND CAPITAL BUDGETS; ACQUISITIONS AND CAPITAL EXPENDITURES MEETING A CERTAIN FINANCIAL THRESHOLD; BORROWINGS, GUARANTIES, LOAN, AND BOND ISSUANCE MEETING A CERTAIN FINANCIAL THRESHOLD; CREATION OF A NEW (OR ACQUISITION OF A CONTROLLING INTEREST IN AN EXISTING) CORPORATION, PARTNERSHIP OR LIMITED LIABILITY COMPANY; AND ADOPTION OF OR AMENDMENTS TO INDIVIDUAL CORPORATE INVESTMENT GUIDELINES. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body There were no committees with the authority to act on behalf of the governing body. Form 990, Part VI, Line 11b Review of form 990 by governing body A COPY OF THE FORM 990 IS REVIEWED BY THE RISK, AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS OF CITY OF HOPE, WHICH ASSISTS THE BOARD IN FULFILLING ITS RESPONSIBILITIES REGARDING FINANCIAL, ACCOUNTING, AND CORPORATE COMPLIANCE MATTERS OF THE BECKMAN RESEARCH INSTITUTE. THE FORM 990 INFORMATION IS COMPILED BY THE ENTERPRISE CONTROLLER'S TAX FUNCTION AND PROVIDED TO EY, AN EXTERNAL ACCOUNTING FIRM, FOR THE PREPARATION OF FORM 990, WHICH IS REVIEWED THOROUGHLY WITH INTERNAL LEADERSHIP AND EXTERNAL PARTICIPANTS, INCLUDING EY, AND RETAINED OUTSIDE TAX COUNSEL. PRIOR TO FILING, THE BECKMAN RESEARCH INSTITUTE FORM 990 IS MADE AVAILABLE TO VOTING MEMBERS OF THE CITY OF HOPE BOARD OF DIRECTORS FOR REVIEW. Form 990, Part VI, Line 12c Conflict of interest policy ALL EMPLOYEES OF CITY OF HOPE AND AFFILIATES, BOARD OF DIRECTORS MEMBERS, BOARD COMMITTEE MEMBERS AND RESEARCH TEAM MEMBERS ARE COVERED BY CITY OF HOPE'S APPLICABLE CONFLICT OF INTEREST POLICIES. DETERMINATIONS AS TO WHETHER A CONFLICT OF INTEREST EXISTS AND REVIEW OF CONFLICT DISCLOSURES ARE MADE BY THE GENERAL COUNSEL AND CHIEF ETHICS AND COMPLIANCE OFFICER OF CITY OF HOPE AND, AS APPLICABLE, THE CHAIR OF THE BOARD OR THE CONFLICT OF INTEREST AND COMMITMENT COMMITTEE, BASED UPON THE CLASSIFICATION OF PERSON MAKING THE DISCLOSURE. RESTRICTIONS IMPOSED ON PERSONS WITH A CONFLICT VARY, BASED UPON THE FACTS, AND MAY INCLUDE: PROHIBITION FROM PARTICIPATING IN A GOVERNING BODY'S DELIBERATIONS AND VOTING ON A GIVEN TRANSACTION OR SET OF TRANSACTIONS; RECUSAL FROM THE DECISION-MAKING PROCESS RELATING TO BUSINESS TRANSACTIONS (E.G., PURCHASING DECISIONS); PROHIBITION FROM PARTICIPATING AS A PRINCIPAL INVESTIGATOR IN RESEARCH; AND DISCLOSURE OF FINANCIAL INTEREST IN RESEARCH STUDY INFORMED CONSENT FORMS AND PUBLICATIONS. As part of a conflict management plan, MONITORING TRANSACTIONS FOR CONFLICTS OF INTEREST IS DONE THROUGH REQUIRED DISCLOSURES AND UPDATES BY PERSONS COVERED BY THE ORGANIZATION'S CONFLICT OF INTEREST POLICIES. CITY OF HOPE'S POLICY PROVIDES FOR DISCIPLINARY ACTION AGAINST PERSONS COVERED BY THE CONFLICT OF INTEREST POLICIES WHO DO NOT COMPLY WITH POLICY REQUIREMENTS. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE"), PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF THE PRESIDENT AND CEO. THE COMMITTEE ALSO SERVES AS THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE CASH COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTOR'S OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. THE COMMITTEE TARGETS THE 75TH PERCENTILE OF TOTAL CASH COMPENSATION OF THE MARKET IN WHICH CITY OF HOPE COMPETES FOR EXECUTIVES. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS AN ANNUAL COMPENSATION REVIEW FOR THE PRESIDENT AND CEO AND THIS WAS LAST COMPLETED ON DECEMBER 9, 2021. ADDITIONALLY, AND WITH RESPECT TO THE FILING DATE OF THIS RETURN, THE MOST RECENT REVIEW OF COMPENSATION PERFORMED BY THE COMMITTEE WAS COMPLETED IN DECEMBER 2022. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE") PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF, OR ESTABLISHING COMPENSATION LEVELS FOR TOTAL COMPENSATION CONSISTENT WITH CITY OF HOPE'S COMPENSATION PHILOSOPHY, FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL. THE COMMITTEE ALSO SERVES AS THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE CASH COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTOR'S OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. THE COMMITTEE TARGETS THE 75TH PERCENTILE OF TOTAL CASH COMPENSATION OF THE MARKET IN WHICH CITY OF HOPE COMPETES FOR EXECUTIVES. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI-YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL, AND THIS WAS LAST COMPLETED ON DECEMBER 9, 2021. ADDITIONALLY, AND WITH RESPECT TO THE FILING DATE OF THIS RETURN, THE MOST RECENT REVIEW OF COMPENSATION PERFORMED BY THE COMMITTEE WAS COMPLETED IN DECEMBER 2022. Form 990, Part VI, Line 19 Required documents available to the public THE BECKMAN RESEARCH INSTITUTE'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC FROM THE SECRETARY OF STATE. CITY OF HOPE'S CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE CITY OF HOPE WEBSITE, AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CONFLICT OF INTEREST MANAGER. THE BECKMAN RESEARCH INSTITUTE'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. Form 990, Part VII, Section A Average Hours Devoted FULL TIME EXEMPT EMPLOYEES GENERALLY WORK IN EXCESS OF 40 HOURS PER WEEK, WHICH HAS BEEN REFLECTED on Form 990, PART VII, Section A, Column (B), BY AN ESTIMATE OF 60 HOURS PER WEEK. THE MEMBERS OF THE BOARD OF DIRECTORS ARE NOT COMPENSATED FOR SERVING ON THE BOARD. THE AVERAGE HOURS REPORTED FOR EACH DIRECTOR IS AN ESTIMATE OF THE TIME SPENT PREPARING FOR AND ATTENDING MEETINGS OF THE BOARD OF DIRECTORS. The board of directors held four regularly scheduled meetings during fiscal year 2022. The Risk, Audit and Compliance Committee Held four regularly scheduled meetings in Fiscal Year 2022. Form 990, Part VII, Section B, Line 1, Column (C) Compensation Paid to Independent Contractors It is possible that a portion of the amounts reported for construction services include reimbursement for expenses, in addition to amounts paid for services. However, the amounts are not distinguishable from one another. Form 990, Part IX, Line 11g Other Fees Purchased Services - Total Expense: 1089868, Program Service Expense: 786287, Management and General Expenses: 303494, Fundraising Expenses: 87; Consulting & Management Fees - Total Expense: 15009418, Program Service Expense: 9935761, Management and General Expenses: 5072544, Fundraising Expenses: 1113; Staffing Fees - Total Expense: 3752332, Program Service Expense: 2482337, Management and General Expenses: 1269717, Fundraising Expenses: 278; Stipends & Honoraria - Total Expense: 1942898, Program Service Expense: 1299144, Management and General Expenses: 643609, Fundraising Expenses: 145; Other Contracted Services - Total Expense: 25960434, Program Service Expense: 17173998, Management and General Expenses: 8784512, Fundraising Expenses: 1924; - Total Expense: , Program Service Expense: , Management and General Expenses: , Fundraising Expenses: ; Form 990, Part XI, Line 9 Other changes in net assets or fund balances Change in Fair Value of Interest Rate Swap Agreement - 9446377; Schedule F, Part I, Line 3(e) Activities in Region(s) INVESTMENT ACTIVITIES OF THE BECKMAN RESEARCH INSTITUTE INCLUDE INVESTMENTS IN MULTIPLE VEHICLES THAT PROVIDE INVESTMENT INCOME AND RETURNS TO THE INSTITUTION TO FURTHER ITS MISSION AND PROGRAMS. AS A RESULT, THERE ARE INVESTMENTS HELD IN OFFSHORE HEDGE FUNDS, MAINLY REGISTERED AS CAYMAN Island EXEMPTED CORPORATIONS. THESE INVESTMENTS HELP MITIGATE RISK IN THE PORTFOLIO AND REPRESENT APPROXIMATELY 17.27 PERCENT OF THE BECKMAN RESEARCH INSTITUTE'S OVERALL CASH AND INVESTMENT PORTFOLIO. THE BECKMAN RESEARCH INSTITUTE'S ALTERNATIVE INVESTMENTS CONSIST OF EQUITY COMMINGLED FUNDS THAT INVEST PRIMARILY IN MARKETABLE SECURITIES AND FUND LIMITED PARTNERSHIPS. VARIOUS STRATEGIES SEEK TO ACHIEVE ATTRACTIVE RISK ADJUSTED RETURNS ACROSS PUBLIC AND PRIVATE EQUITY AND DEBT SECURITIES, DERIVATIVES, PRIVATE COMPANIES, VENTURE CAPITAL, REAL ESTATE, ETC. THESE ALTERNATIVE INVESTMENTS MAY INVEST IN BOTH REGISTERED AND NON-REGISTERED SECURITIES IN THE U.S. AND GLOBALLY, WITH EXPOSURE TO BOTH EMERGING AND DEVELOPED MARKETS. THE BECKMAN RESEARCH INSTITUTE'S HEDGE FUND INVESTMENTS CONSIST OF DIRECT AND MULTI-MANAGER "HEDGE FUND OF FUND" INVESTMENTS. STRATEGIES INCLUDE LONG/SHORT EQUITY, LONG/SHORT CREDIT, AND OTHER STRATEGIES. INVESTMENTS IN HEDGE FUNDS HAVE LIMITED LIQUIDITY AND MAY BE SUBJECT TO VARIOUS LOCKUP PERIODS, REDEMPTION FEES, AND NOTICE REQUIREMENTS. HEDGE FUNDS TYPICALLY RESERVE THE RIGHT TO REDUCE OR SUSPEND REDEMPTIONS (GATING EVENT) AND TO SATISFY REDEMPTIONS BY MAKING DISTRIBUTIONS IN KIND, UNDER CERTAIN CIRCUMSTANCES. ADDITIONALLY, HEDGE FUNDS MAY HOLD, DIRECTLY OR INDIRECTLY, SIDE-POCKET INVESTMENTS WHERE NO REDEMPTIONS ARE PERMITTED UNTIL SUCH INVESTMENTS ARE LIQUIDATED OR DEEMED REALIZED. REDEMPTION PERIODS RANGE MONTHLY, QUARTERLY, OR ANNUALLY WITH NOTICE REQUIREMENTS BETWEEN 30 TO 90 DAYS. The Beckman Research Institute ALSO INVESTS IN FUND LIMITED PARTNERSHIPS WITH PRIVATE EQUITY LIKE TERMS, INCLUDING CAPITAL CALLS DURING ITS INVESTMENT PERIOD. THESE SELECT FUNDS, WHICH ARE CURRENTLY OPPORTUNISTIC CREDIT STRATEGIES, ARE CLASSIFIED UNDER HEDGE FUNDS. THE BECKMAN RESEARCH INSTITUTE'S PRIVATE EQUITY INVESTMENTS CONSIST OF FUND LIMITED PARTNERSHIPS. STRATEGIES INCLUDE BUYOUT, VENTURE/GROWTH CAPITAL, DEBT, AND SECONDARY PRIVATE EQUITY. FUND TERMS ARE TYPICALLY TEN YEARS OR GREATER. BECKMAN RESEARCH INSTITUTE MAY NOT WITHDRAW, SELL, ASSIGN, OR TRANSFER ITS INTERESTS IN THESE FUNDS, EXCEPT IN CERTAIN, VERY LIMITED CIRCUMSTANCES, SUBJECT TO CONSENT BY THE GENERAL PARTNERS OF THE FUNDS. ALL OF THESE INVESTMENTS HAVE BEEN INCLUDED IN FORM 990, PART X, LINE 12. Beckman Research Institute had one employee outside of the United States and they have been disclosed on Schedule F, Part I, Line 3. RESEARCH SYMPOSIA CONSIST OF SCIENTIFIC MEETINGS THAT THE BECKMAN RESEARCH INSTITUTE PRINCIPAL INVESTIGATORS AND OTHER RESEARCH STAFF ATTEND FOR EDUCATIONAL, RESEARCH AND SCIENTIFIC PURPOSES AND TO PRESENT AND SHARE RESEARCH OBJECTIVES AND RESULTS. RESEARCH ACTIVITIES SPAN GLOBALLY AND RESEARCH SYMPOSIA ARE OFTEN CONDUCTED IN THE VARIOUS REGIONS IDENTIFIED IN SCHEDULE F. CITY OF HOPE SUPPORTS ATTENDANCE OF OUR RESEARCH STAFF AT THESE SYMPOSIA. City of Hope 1500 East Duarte Road Duarte CA 91010 953435919 Fundraising CA 501(c)(3) 7 NA false City of Hope National Medical Center 1500 East Duarte Road Duarte CA 91010 951683875 Hospital CA 501(c)(3) 3 City of Hope true City of Hope Medical Foundation 1500 East Duarte Road Duarte CA 91010 274803222 Healthcare CA 501(c)(3) 3 City of Hope true The Translational Genomics Research Institute 445 N 5th Street Suite 600 Phoenix AZ 85004 753065445 Research AZ 501(c)(3) 7 City of Hope true The Translational Genomics Research Institute Foundation 445 N 5th Street Suite 120 Phoenix AZ 85004 331092191 Fundraising AZ 501(c)(3) 7 TGEN true COH HoldCo Inc 1500 East Duarte Road Duarte CA 91010 873651176 Support DE 501(c)(3) Type III-FI City of Hope true AccessHope LLC 1500 East Duarte Road Duarte CA 91010 842818450 Oncology Support DE NA N/A Southern California Radiation Oncology LLC 1500 East Duarte Road Duarte CA 91010 364887584 Radiation Oncology DE NA N/A COH HOLDCO INC (converted to tax-exempt on 93022) 1500 EAST DUARTE ROAD DUARTE CA 91010 873651176 SUPPORT DE CITY OF HOPE C Corporation true false false true false false false false false false false false true true false true true true false false CITY OF HOPE NATIONAL MEDICAL CENTER L 2074097 Book CITY OF HOPE NATIONAL MEDICAL CENTER M 63555987 Book CITY OF HOPE NATIONAL MEDICAL CENTER O 43812888 Book CITY OF HOPE NATIONAL MEDICAL CENTER P 33530749 Book CITY OF HOPE NATIONAL MEDICAL CENTER Q 9883901 Book CITY OF HOPE MEDICAL FOUNDATION O 234593 Book The Translational Genomics Research Institute C 123597 Book